SynAct Pharma to present resomelagon preclinical RA data in 2026
SynAct Pharma will present new resomelagon preclinical data on a Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.